USP <601>
USP <601> anchors performance testing for inhalation and nasal aerosols, sprays, and powders.
AccreditedStandards
Breathing Simulation: USP <601> and FDA OINDP
Standards for inhaled dose, actuation timing, patient breathing profiles, and simulated-use recovery studies.
Use this cluster when device performance depends on the selected breath profile, patient interface, sample recovery, assay outputs, and FDA or USP documentation expectations.
Standard roster
Individual standards in this cluster
USP <601> and FDA OINDP guidances form the citation set; ARE Labs translates them into breath profile selection, simulator setup, actuation timing, recovery, assay readiness, and reporting controls.
FDA MDI / DPI
FDA MDI / DPI quality guidance supports protocol rationale for inhalation aerosols and powders.
AlignedFDA nasal aerosols / sprays
FDA nasal aerosols and sprays guidance provides related OINDP context for local-action comparative studies.
AlignedPurpose & when to use
Breathing simulation and inhalation profile studies help evaluate aerosol dose delivery when performance depends on patient breathing patterns, device timing, interface geometry, or use conditions. This Standards cluster helps teams determine how USP <601> and FDA OINDP guidance should inform simulated-use protocols for inhalers, nebulizers, nasal products, oral sprays, masks, and related interfaces:
- MDI and DPI teams use USP <601> and FDA OINDP guidance when actuation timing and inhaled dose need one protocol.
- Nasal programs use FDA nasal guidance when local-action BA or BE planning depends on spray performance and comparative dose evidence.
- Device-interface studies use USP <601> context when patient-facing fixtures, breathing profiles, and dose recovery must be documented together.
- Development programs use FDA quality expectations to connect formulation changes, breath profiles, analytical recovery, and submission-ready report tables.
Use this cluster when the central question is whether simulated breathing conditions, collection interfaces, dose recovery, analytical assay, and documented deviations can be traced from protocol setup through final interpretation.
Applicable to
Built around simulated-use dose decisions
The cluster applies when emitted or inhaled dose depends on patient breathing patterns, actuation coordination, device-to-patient interfaces, and recovery controls across inhalation or adjacent spray formats.
Standards in this group
What each citation controls
This page is a cluster, not an individual standard summary. USP <601> supplies the compendial performance-quality frame for inhalation and nasal products, while FDA OINDP guidances add development, quality, and comparative-study context. ARE Labs uses the citations to define protocol boundaries, simulator controls, recovery evidence, and report language.
USP
AccreditedUSP <601>
Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders - Performance Quality Tests
USP <601> anchors performance testing for inhalation and nasal aerosols, sprays, and powders. For breathing simulation, it informs device setup, delivered-dose context, recovery controls, analytical readiness, and report language when simulated patient use must connect to compendial performance evidence.
USP official preview page verified 2026-05-17; public preview cites United States Pharmacopeia (2023).
FDA
AlignedFDA MDI / DPI
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations
FDA MDI / DPI quality guidance supports protocol rationale for inhalation aerosols and powders. ARE Labs uses it to connect breath profile selection, actuation coordination, dose quantification, recovery checks, formulation or device changes, and CMC-oriented reporting where applicable.
FDA official guidance page verified 2026-05-17; page identifies April 2018 draft guidance.
FDA
AlignedFDA nasal aerosols / sprays
Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action
FDA nasal aerosols and sprays guidance provides related OINDP context for local-action comparative studies. On this page, it helps frame nasal dose delivery, spray performance links, recovery documentation, and when breathing simulation should be paired with other in vitro evidence.
FDA official PDF verified 2026-05-17; document identifies April 2003 draft guidance.
Accredited where held, aligned where followed
This page separates formal accreditation from standards alignment. ARE Labs can cite accredited USP <601> scope where applicable; FDA MDI / DPI and FDA nasal aerosols / sprays guidance are treated as aligned regulatory frameworks followed by protocol.
- USP <601>AccreditedAccredited performance-quality frame where scope applies.
- FDA MDI / DPIAlignedDraft quality guidance translated into protocol controls.
- FDA nasal aerosols / spraysAlignedDraft BA/BE context used for nasal study rationale.
Operational chain
How ARE Labs turns the standards into a study
The citations define the study frame, but the final method still has to match the product, interface, breath profile, assay, and regulatory objective. ARE Labs translates USP and FDA expectations into controlled simulator execution and reviewable outputs.
01
Configuration
Select the breathing profile
We map USP <601> and FDA OINDP objectives to profile shape, flow range, inhalation volume, interface geometry, sampling train, and collection strategy.
Profile rationale02
Timing
Coordinate device actuation
FDA MDI / DPI quality questions often depend on actuation timing, device conditioning, breath trigger behavior, orientation, and repeatable simulated-use handling.
Timing record03
Recovery
Control captured dose
USP <601> context guides recovery, extraction readiness, blanks, replicates, and assay handoff when inhaled or emitted dose must be quantified.
Recovery package04
Adaptation
Document fit-for-purpose choices
When no FDA or USP citation exactly matches the device, ARE Labs records the adaptation rationale, limitations, and interpretation impact before reporting.
Rationale log05
Reporting
Connect results to the citation set
Reports link breathing profiles, dose results, recovery, assay outputs, deviations, and limitations back to USP <601> and FDA OINDP expectations.
Review-ready reportData quality, QA/QC & documentation
Breathing simulation data are useful only when the supporting records are clear and traceable. ARE Labs connects USP and FDA study framing with documented simulator settings, actuation timing, flow verification, sample recovery, assay readiness, raw data retention, and study deviations so reviewers can follow how each result was produced.
Connect profile to objective
USP <601> and FDA OINDP studies link breathing profile, simulator configuration, interface, and collection train to the stated study objective.
Preserve simulated-use controls
FDA MDI / DPI records capture actuation timing, device orientation, breath trigger behavior, conditioning, and repeatability checks.
Retain dose evidence
USP <601> work preserves recovered mass, extraction notes, assay handoff, blanks, replicate logic, and calculation references.
Document method adaptations
When FDA or USP language does not match the device, ARE Labs records rationale, limitation, and interpretation impact.
Separate scope from alignment
ISO 17025 review language distinguishes accredited USP <601> work from aligned FDA OINDP guidance followed by protocol.
Why ARE Labs
ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.
Reviewed byJamie Balarashti - Weston Schaper
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported
Common questions
These questions address how inhalation, formulation, device, and quality teams determine whether breathing simulation work should follow USP <601>, FDA MDI / DPI quality guidance, FDA nasal guidance, or a blended study plan. The answers outline the practical scoping decisions ARE Labs resolves before drafting the protocol, planning samples, and preparing the report.
Q. Which citation applies?
A. The appropriate framework depends on the dosage form, device type, route, and study objective. USP <601> commonly frames inhalation and nasal product performance, while FDA OINDP guidance provides additional context for development, quality, and comparative studies.
Q. Is breathing simulation accredited?
A. ARE Labs can cite its accredited USP <601> scope when applicable. FDA guidances are regulatory references used to align the protocol; they are not separate accreditation claims.
Q. What if profiles are custom?
A. Custom breathing profiles may be used when justified by the device use, patient population, or study objective. ARE Labs documents that rationale before interpreting the results.
Q. Can assays be included?
A. Yes. When dose quantification is required, the study plan can pair simulator collection with sample recovery, extraction, HPLC or another assay workflow, and report tables.
Q. Does this certify products?
A. No. ARE Labs performs testing aligned with the cited standards or guidance. Certification, regulatory approval, and labeling decisions remain with the responsible authority.
Related services & devices
Related services & devices
Service
Breathing Simulation
Simulated breathing profiles, patient interfaces, actuation timing, and inhaled dose recovery.Read more ->ServiceDose Uniformity & Emitted Dose
Delivered-dose and emitted-dose evidence for OINDP and simulated-use workflows.Read more ->ServicePSD Testing
Particle-size distribution evidence when breathing simulation connects to aerosol performance.Read more ->ServiceSpray Pattern & Plume Geometry
Imaging evidence for nasal, oral, and aerosolized spray performance questions.Read more ->ServiceHigh-Speed Imaging & Velocimetry
Timing and flow visualization for actuation, plume, and interface behavior.Read more ->ServiceInhalation Risk Assessment
Exposure-oriented inhalation studies when simulated breathing informs risk interpretation.Read more ->DevicesMetered Dose Inhalers
MDI products where actuation timing and dose recovery drive study design.Read more ->DevicesDry Powder Inhalers
DPI products where patient flow and powder emission must be coordinated.Read more ->DevicesNebulizers
Nebulized products where delivery during breathing is the core question.Read more ->DevicesNasal Drug Spray Devices
Nasal products where spray performance and local-action evidence are related.Read more ->Related clusters
Related standards clusters
Breathing simulation often sits next to particle sizing, dose uniformity, nebulizer performance, and spray imaging standards. These clusters help route adjacent evidence packages without forcing one citation to cover every study question.
Standards - Live